Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-936557 for active ulcerative colitis
2010-022506-41Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in autoimmune colitis comparing BMS-936557 with Placebo (2 arms). Primary endpoint: Induction of clinical remission at Week 11. Started Feb 2011; status: terminated.
02
Drugs
eldelumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2010-022506-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022506-41.